Main > > >BONE CANCER. *

---

Metastasis. From Solid Tumors. TREAT.:
DenosuMAb.
CA Approval Date : ?
EU Approval Date : 2011. 07.15.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.13.




Metastasis. From Solid Tumors. TREAT.:
Zoledronic Acid Inj. IV.
USA Initial Approval Year: 2001.
(*) Company : Novartis.
Patent : USA Expiration: 2012.11.
TradeMark: Zometa.
UpDate: 2018. 06.13.




OsteoSarcoma. Indication. Levoleucovorin.
(Brand)
Post High-Dose Methotrexate Rescue.
USA Approval Date: 2008. 03.07.
(*) Company : Spectrum Pharma.
Patent : USA 6,500,829
Expired
TradeMark: Fusilev
Web-Site : www.fusilev.com/
UpDate: 2018. 06.13.




OsteoSarcoma. Indication. Levoleucovorin.
(Generic)
Post High-Dose Methotrexate Rescue.
USA Launch Date: 2017. 03.28.
(*) Company: Amneal Pharma.
UpDate: 2018. 06.13.




OsteoSarcoma. TREAT.: Mifamurtide.
+Post-Operative Multi-Agent CT
>PostResection (Surgery)
EU Approval Date: 2009. 03.09.
(*) Company : Takeda Oncology.
TradeMark: Mepact
UpDate: 2018. 06.13.




Pain. TREAT.: Strontium Chloride Sr89.
(Metastatic)
USA Approval Date: 2016. 09.07.
USA Approval Date: 2019. 11.20.>MFG.
USA Launch Date: 2020. 02.13.
(*) Company : Q Biomed.
Distribution USA: Jubilant Radio-
pharma.
Web-Site : strontium89.com
UpDate: 2020. 02.15.




Pain. TREAT.: UltraSound>Palliation.
(Metastatic)
CA Approval Date : 2013. 08.21
USA Approval Date: 2012. 10.22
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 06.13.







>BONE CANCER. *'s products
This section has no products